TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00163280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATL-104
Description: Daily does of ATL-104 (50,100 or 150mg) or placebo for 3 days prior to the start of chemotherapy and peripheral blood stem cell transplantation. Following stem cell transplantation patients received 3 further daily doses of ATL-104 (50, 100 or 150mg) or placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATL-104
Description: Daily does of ATL-104 (50,100 or 150mg) or placebo for 3 days prior to the start of chemotherapy and peripheral blood stem cell transplantation. Following stem cell transplantation patients received 3 further daily doses of ATL-104 (50, 100 or 150mg) or placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATL-104
Description: Daily does of ATL-104 (50,100 or 150mg) or placebo for 3 days prior to the start of chemotherapy and peripheral blood stem cell transplantation. Following stem cell transplantation patients received 3 further daily doses of ATL-104 (50, 100 or 150mg) or placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ATL-104
Description: Daily does of ATL-104 (50,100 or 150mg) or placebo for 3 days prior to the start of chemotherapy and peripheral blood stem cell transplantation. Following stem cell transplantation patients received 3 further daily doses of ATL-104 (50, 100 or 150mg) or placebo.
Study: NCT05180643

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction-based program (MBSR).
Description: The MBSR program is built over 8 weeks (1 information session, 8 group sessions from 2h30 to 3h and 1 full day). A trained MBSR instructor will lead group sessions weekly for approximately 150-210 minutes to teach and demonstrate the practices. Practices include walking/standing/supine meditation, body scanning (drawing attention to various areas of the body such as the right foot or left hand), and simple hatha yoga postures. Exercises are the basis of this group learning with practice time and practice exchange time. Participants are asked to commit to daily meditation at home using audioguides for 40 minutes to 1 hour.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction-based program (MBSR).
Description: The MBSR program is built over 8 weeks (1 information session, 8 group sessions from 2h30 to 3h and 1 full day). A trained MBSR instructor will lead group sessions weekly for approximately 150-210 minutes to teach and demonstrate the practices. Practices include walking/standing/supine meditation, body scanning (drawing attention to various areas of the body such as the right foot or left hand), and simple hatha yoga postures. Exercises are the basis of this group learning with practice time and practice exchange time. Participants are asked to commit to daily meditation at home using audioguides for 40 minutes to 1 hour.
Study: NCT01862380

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional explorations
Description: Functional explorations of cortisol and aldosterone production during stimulation by ITT and sodium depletion respectively

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional explorations
Description: Functional explorations of cortisol and aldosterone production during stimulation by ITT and sodium depletion respectively
Study: NCT00571467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRTX-100 (Staphylococcal protein A)
Description: 4 weekly IV (in the vein) doses of 1 of the 3 following PRTX-100 dose levels:~* Cohort 1: 0.075 mcg/kg~* Cohort 2: 0.15 mcg/kg~* Cohort 3: 0.30 mcg/kg
Study: NCT00818779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: 150 - 300 mg once daily for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: 5-10 mg once daily for 6 weeks
Study: NCT02302378

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar paramedian approach at L3-L4 interspace
Description: Spinal anesthesia will be performed via a lumbar paramedian approach at L3-L4 interspace using 12.5mg 0.5% Bupivacaine (preservative free)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Taylor's approach (paramedian approach at L5-S1 interspace)
Description: Spinal anesthesia will be performed via Taylor's approach (paramedian approach at L5-61 interspace) using 12.5mg 0.5% Bupivacaine (preservative free)
Study: NCT03682302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: EXPAREL 4mg/kg (maximum 266 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: EXPAREL 4mg/kg (maximum 266 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: EXPAREL 4mg/kg (maximum 266 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% Bupivacaine HCl
Description: Bupivacaine HCl 2mg/kg
Study: NCT03793036

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: preoperative nutrition
Description: The participants of experimental group received 400 mil of a clear carbohydrate drink (12,5 gr/100 mil carbohydrate, 50 kcal/100ml, pH 5.0) at 10:00 pm the evening before surgery and another 200 mil of the carbohydrate drink on the day of surgery, 2 hours before induction of anesthesia. After surgery the participants fasted until the recovery of function of the bowel.
Study: NCT00939159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Description: 20 mg capsules by mouth 3 times a week for 3 weeks in a 28-day cycle.
Study: NCT01393145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Fluticasone /Formoterol 12/250 μg
Description: Capsules containing Fumarate formoterol 12 µg + fluticasone propionate 250 µg dry powder for inhalation with aerocaps®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seretide Diskus (salmeterol/fluticasone) 50/250 μg
Description: Capsules containing salmeterol xinafoate 72.5 µg (equivalent to 50 µg of salmeterol) presented as powder for aspiration, packed in a plastic device in disk format, containing 60 doses
Study: NCT02915146

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: combined ultraviolet phototherapy (NB-UVB + UVA1) vs. NB-UVB monotherapy
Description: NB-UVB combined with UVA1

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: combined ultraviolet phototherapy (NB-UVB + UVA1) vs. NB-UVB monotherapy
Description: NB-UVB combined with UVA1
Study: NCT03740763

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Cord Stimulation (SCS)
Description: SCS for treatment of neuropathic pain

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Cord Stimulation (SCS)
Description: SCS for treatment of neuropathic pain
Study: NCT00856440

Intervention type: DRUG
Intervention: Fleets Oral Sodium Phosphate Solution (OSPS)
Description: Osmotic preparation for colonoscopy

Intervention type: DRUG
Intervention: Fleets Oral Sodium Phosphate Solution (OSPS)
Description: Osmotic preparation for colonoscopy
Study: NCT03740763

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Physiotherapy 2 hours/week with physiotherapist and physical activity counseling for treatment of neuropathic pain

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Physiotherapy 2 hours/week with physiotherapist and physical activity counseling for treatment of neuropathic pain
Study: NCT04619784

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates Exercises
Description: Patients will receive 12 sessions of pilates.

Intervention type: OTHER
Group type: OTHER
Intervention: control
Description: Their routine medical treatments were continued
Study: NCT02250339

Intervention type: OTHER
Intervention: LAKU family program
Description: Multi-systemic and multicomponent family-based intervention program

Intervention type: OTHER
Intervention: Etä-LAKU family program
Description: Ecosystem-based intervention for families living in rural parts of Finland

Intervention type: OTHER
Intervention: Family therapy
Description: Treatment as usual (TAU)
Study: NCT01898247

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation-based mastery learning
Description: Internal Medicine residents are randomly selected to undergo simulation-based mastery learning.
Study: NCT01463787

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microsurgical varicocelectomy in inguinal approach
Description: In inguinal approach, the incision, which was about 3cm, was made two fingers up the pubic symphysis, from external inguinal rings parallel to the inguinal ligament.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: microsurgical varicocelectomy in subinguinal approach
Description: In subinguinal approach, the incision was about 3 cm horizontal and 1 cm below the external inguinal ring.
Study: NCT02993848

Intervention type: OTHER
Intervention: No intervention
Study: NCT00856440

Intervention type: DRUG
Intervention: Colyte
Description: Lavage preparation for colonoscopy

Intervention type: DRUG
Intervention: Colyte
Description: Lavage preparation for colonoscopy

Intervention type: DRUG
Intervention: Dual (OSPS & Colyte)
Description: Combined, two-day preparation utilizing both preparations

Intervention type: DRUG
Intervention: Dual (OSPS & Colyte)
Description: Combined, two-day preparation utilizing both preparations
Study: NCT03540563

Intervention type: OTHER
Group type: OTHER
Intervention: Blood draw
Description: Blood will be drawn to assess ctDNA
Study: NCT01098318

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Herbal extract
Description: 340-1,360 mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: 50-200 mg daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lactose monohydrate
Description: 1-4 capsules daily
Study: NCT03581760

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycling Exercise
Description: Cycling exercise will be performed in the patients once a day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physiotherapy
Description: Conventional physiotherapy will be performed in the patients twice a day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physiotherapy
Description: Conventional physiotherapy will be performed in the patients twice a day.
Study: NCT01369771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafluprost 0.0015%
Description: Eye Drops, Solution. Topical Use. One single-unit dose pipet of 0.3 ml solution including 0.0015 mg/ ml of Tafluprost once daily in the affected eye(s)for 12 months.
Study: NCT02421575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00655018

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin treatment (alpha tocopherol plus ascorbic acid)
Description: alpha tocopherol 600 IU/d plus ascorbic acid 500 mg/d and lifestyle intervention \[hypocaloric Diet(25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity\].

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo and lifestyle intervention \[hypocaloric Diet(25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity\].
Study: NCT02800551

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: dose-intensified image-guided SBRT using simultaneous integrated boost

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: dose-intensified image-guided SBRT using simultaneous integrated boost

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External 3-dimensional conformal radiotherapy (3D-CRT)
Study: NCT02712710

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: functional knee brace
Description: The functional knee brace for OA can decrease abnormal varus torque by external force.
Study: NCT01632540

Intervention type: DRUG
Intervention: Beclomethasone Dipropionate (BDP) Nasal Aerosol
Description: BDP nasal aerosol 320 mcg/day will be administered to all patients as 2 sprays in each nostril once daily.
Study: NCT02546622

Intervention type: BIOLOGICAL
Intervention: Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013
Description: Prophylaxis for prevention of bleeding, various regimens.

Intervention type: BIOLOGICAL
Intervention: Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013
Description: Prophylaxis for prevention of bleeding, various regimens.

Intervention type: BIOLOGICAL
Intervention: Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013
Description: Prophylaxis for prevention of bleeding, various regimens.

Intervention type: BIOLOGICAL
Intervention: Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013
Description: Prophylaxis for prevention of bleeding, various regimens.
Study: NCT01089738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03382792 0.5mg
Description: 0.5 mg PF-03382792, qd, for 14 days or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03382792 1.5 mg
Description: 1.5 mg PF-03382792, qd, for 14 days or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03382792 5 mg
Description: 5 mg PF-03382792, qd, for 14 days or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03382792 15 mg
Description: 15 mg PF-03382792, qd, for 14 days or placebo
Study: NCT01028729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: 7.5mg/m2/day, iv, from day 1 to day 14
Study: NCT01574196

Intervention type: OTHER
Intervention: Autonomic nervous system activity records
Description: The description of autonomic equilibrium is based on the use of non-invasive tools such as Holter-ECG monitor (24 hours) which is suitable for longitudinal follow up of cohorts of patients. This tool allows the analysis of instantaneous or delayed variability of the heart rate, in the Hertzian frequency domain after extraction and mathematical transformation of a temporal sequence of R-R spaces from the ECG signal.
Study: NCT01135303

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VistaO2 device
Description: Full night VistaO2 device monitoring synchronized with the gold standard polysomnography.
Study: NCT04630288

Intervention type: DRUG
Intervention: Clopidogrel
Description: Describe the safety of Ticagrelor vs Clopidogrel use, in patients with ACS in terms of major bleeding between 30 days and one year after the index ACS event. An ITT approach and IPCW method to adjust for change of initial treatment will be used for the analysis.
Study: NCT01028729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine-Cisplatin chemotherapy
Description: Gemcitabine 1000 mg/m2, iv, on day 1, 8 Cisplatin 80mg/m2, iv, on day 1, 2, 3
Study: NCT03490955

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: salad dressing (canola oil) and black pepper
Description: Subjects will consume a vegetable salad with black pepper and dressing (canola oil) one time in the morning

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: salad dressing (canola oil)
Description: Subjects will consume a vegetable salad with dressing (canola oil) one time in the morning

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: black pepper
Description: Subjects will consume a vegetable salad without dressing (canola oil) but with black pepper one time in the morning
Study: NCT04630288

Intervention type: DRUG
Intervention: Ticagrelor
Description: Describe the safety of Ticagrelor vs Clopidogrel use, in patients with ACS in terms of major bleeding between 30 days and one year after the index ACS event. An ITT approach and IPCW method to adjust for change of initial treatment will be used for the analysis.
Study: NCT04842370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PHI-101
Description: PHI-101, oral, once-daily administration, consisting of 28-days per 1 cycle
Study: NCT03490955

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: salad
Description: Subjects will consume a vegetable salad without dressing (canola oil) and without black pepper one time in the morning

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Salad dressing (olive oil) and black pepper
Description: Subjects will consume a vegetable salad with black pepper and dressing (olive oil) one time in the morning

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Salad dressing (corn oil) and black pepper
Description: Subjects will consume a vegetable salad with black pepper and dressing (corn oil) one time in the morning

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Salad dressing (sunflower oil) and black pepper
Description: Subjects will consume a vegetable salad with black pepper and dressing (sunflower oil) one time in the morning

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Salad dressing (flaxseed oil) and black pepper
Description: Subjects will consume a vegetable salad with black pepper and dressing (flaxseed oil) one time in the morning
Study: NCT04966286

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: multimedia education
Description: The MLEP intervention was based on a literature review of prior research on the content and format of self care related multimedia education programmes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multimedia education
Description: The MLEP intervention was based on a literature review of prior research on the content and format of self care related multimedia education programmes
Study: NCT04557553

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lagenbone
Description: Traditional Chinese medicine herbal formula
Study: NCT02541370

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD133-CAR vector-transduced T cells
Description: genetically engineered lymphocyte therapy
Study: NCT04877353

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIV
Description: NIV applied for approximately 30 to 45 min at 2- to 4-h intervals for 48 h following surgery
Study: NCT02865239

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Position for the 3.0 Tesla in Magnetic Resonance Imaging
Description: Eligible patients will have a standard MRI in prone position. At the end of this examination, all patients will have an other standard MRI in supine position.~This examination is then extended by 10 minutes without additional injection of contrast medium

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Position for the 3.0 Tesla in Magnetic Resonance Imaging
Description: Eligible patients will have a standard MRI in prone position. At the end of this examination, all patients will have an other standard MRI in supine position.~This examination is then extended by 10 minutes without additional injection of contrast medium
Study: NCT01796379

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training
Description: 9 months of high intensity interval based aerobic exercise (3 times/week)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Moderate Training
Study: NCT02260323

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: patient-tailored anti-arthritis herbs
Description: patient use tailored anti-arthritis herbs

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: patient-tailored DMARDs
Description: patient use tailored disease-modifying antirheumatic drugs
Study: NCT03955510

Intervention type: OTHER
Group type: OTHER
Intervention: Right time eating
Description: Right-time eating means breakfast before 8am, lunch before 1 pm and dinner before 6pm. Subjects will be asked to stick to this eating schedule for 1 week. Subjects will randomly be assigned to each eating pattern during the study period. Each subject will be required to do this intervention twice during the study period. One time they will have right time eating with alcohol , the second time the will have this intervention without alcohol.
Study: NCT01073644

Intervention type: DRUG
Intervention: Sunitinib malate
Description: sunitinib 50 mg, 4 weeks on, 2 weeks off
Study: NCT04356937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Patients will receive the standard treatment for COVID-19 per MGH guidance and also be randomized (2:1) to one of the following arms:~1. Tocilizumab 8mg x 1 (n=185)~2. Standard of care/Placebo (n=93)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Patients will receive the standard treatment for COVID-19 per MGH guidance and also be randomized (2:1) to one of the following arms:~1. Tocilizumab 8mg x 1 (n=185)~2. Standard of care/Placebo (n=93)
Study: NCT00570401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Study: NCT01081613

Intervention type: OTHER
Intervention: 89Zr-bevacizumab PET imaging
Description: injection 89Zr-bevacizumab and 89 Zr-bevacizumab PET scan
Study: NCT00003677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolastatin 10
Description: IV bolus once every 21 days.
Study: NCT02244671

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fat, PRP, botulinum toxin
Description: fat injection with platelet-rich-plasma (PRP) after immobilizing the extraocular muscles with botulinum toxin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: botulinum toxin
Description: botulinum toxin used to immobilize extra-ocular muscles prior to fat injection.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRP
Description: autologous PRP is prepared with a dedicated centrifuge at the time of fat harvesting
Study: NCT01811537

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Chordae
Study: NCT03502499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Half-normal saline
Description: Use of half-normal saline as an irrigant for open-irrigated ablation catheters

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Use of normal saline as an irrigant for open-irrigated ablation catheters